Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial.

Autor: Møller-Bisgaard, S^1,2 (AUTHOR) s.moeller.bisgaard@gmail.com, Hørslev-Petersen, K^3,4 (AUTHOR), Ejbjerg, B² (AUTHOR), Hetland, ML^1,5 (AUTHOR), Christensen, R^6,7 (AUTHOR), Ørnbjerg, LM¹ (AUTHOR), Glinatsi, D^1,8 (AUTHOR), Møller, JM⁹ (AUTHOR), Boesen, M¹⁰ (AUTHOR), Stengaard-Pedersen, K¹¹ (AUTHOR), Madsen, OR¹² (AUTHOR), Jensen, B¹³ (AUTHOR), Villadsen, JA¹⁴ (AUTHOR), Hauge, EM¹¹ (AUTHOR), Bennett, P¹² (AUTHOR), Hendricks, O^3,4 (AUTHOR), Asmussen, K¹³ (AUTHOR), Kowalski, M¹⁵ (AUTHOR), Lindegaard, H⁷ (AUTHOR), Bliddal, H¹⁶ (AUTHOR)

Publikováno v: Scandinavian Journal of Rheumatology. Jul2022, Vol. 51 Issue 4, p268-278. 11p.

Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis

Autor: Aldridge, J., Lundell, A. C., Andersson, K., Mark, L., Hetland, M. Lund, Østergaard, M., Uhlig, T., Heiberg, M. Schrumpf, Haavardsholm, E. A., Nurmohamed, M., Lampa, J., Nordström, D., Hørslev-Petersen, K., Gudbjornsson, B., Gröndal, G., van Vollenhoven, R., Rudin, A.

Publikováno v: Clinical and Experimental Rheumatology, 40(7), 1393-1402. Clinical and Experimental Rheumatology S.A.S.
Clinical and experimental rheumatology, 40(7), 1393-1402. Clinical and Experimental Rheumatology S.A.S.
Aldridge, J, Lundell, A C, Andersson, K, Mark, L, Hetland, M L, Østergaard, M, Uhlig, T, Heiberg, M S, Haavardsholm, E A, Nurmohamed, M, Lampa, J, Nordström, D, Hørslev-Petersen, K, Gudbjornsson, B, Gröndal, G, van Vollenhoven, R & Rudin, A 2022, ' Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis ', Clinical and Experimental Rheumatology, vol. 40, no. 7, pp. 1393-1402 . https://doi.org/10.55563/clinexprheumatol/idogmj

Objective In early rheumatoid arthritis (eRA) plasma levels of specific chemokines have been shown to correlate with disease activity. However, it is unclear whether pre-treatment chemokine levels can predict disease remission at week 24, and it is n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efb9c62ef59516aa1c22c4e92de501a8
https://doi.org/10.55563/clinexprheumatol/idogmj

Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial.

Autor: Raft, MB, Hetland, ML, Brahe, CH, Hørslev-Petersen, K, Midtbøll Ørnbjerg, L, Junker, P, Biln, N, Stengaard-Pedersen, K, Østergaard, M

Publikováno v: Scandinavian Journal of Rheumatology; Jul2023, Vol. 52 Issue 4, p342-352, 11p

CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONALTHERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STARTRIAL

Autor: Østergaard, M., Van Vollenhoven, R., Rudin, A., Hetland, M. L., Heiberg, M., Nordström, D., Nurmohamed, M., Gudbjornsson, B., Ørnbjerg, L. Midtbøll, Bøyesen, P., Olsen, I., Lend, K., Hørslev-Petersen, K., Uhlig, T., Sokka-Isler, T., Gröndal, G., Krabbe, S., Lindqvist, J., Gjertsson, I., Glinatsi, D., Kapetanovic, M. C., Aga, A. B., Faustini, F., Parmanne, P., Lorenzen, T., Cagnotto, G., Back, J., Hendricks, O., Vedder, D., Rannio, T., Grenholm, E., Lindegaard, H. M., Ljosa, M. K. A., Brodin, E., Soderbergh, A., Rizk, M., Hermansson, E., Uhrenholt, L., Larsson, P., Just, S. A., Bakland, G., Stevens, D., Laurberg, T. B., Haavardsholm, E. A., Lampa, J.

Publikováno v: Østergaard, M, Van Vollenhoven, R, Rudin, A, Hetland, M L, Heiberg, M, Nordström, D, Nurmohamed, M, Gudbjornsson, B, Ørnbjerg, L M, Bøyesen, P, Olsen, I, Lend, K, Hørslev-Petersen, K, Uhlig, T, Sokka-Isler, T, Gröndal, G, Krabbe, S, Lindqvist, J, Gjertsson, I, Glinatsi, D, Kapetanovic, M C, Aga, A B, Faustini, F, Parmanne, P, Lorenzen, T, Cagnotto, G, Back, J, Hendricks, O, Vedder, D, Rannio, T, Grenholm, E, Lindegaard, H M, Ljosa, M K A, Brodin, E, Soderbergh, A, Rizk, M, Hermansson, E, Uhrenholt, L, Larsson, P, Just, S A, Bakland, G, Stevens, D, Laurberg, T B, Haavardsholm, E A, Lampa, J & NORD-STAR Study Group 2022, ' CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONALTHERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STARTRIAL ', Annals of the Rheumatic Diseases, vol. 81, no. Suppl. 1, OP0058, pp. 38-40 . https://doi.org/10.1136/annrheumdis-2022-eular.868

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7c7e751a9a992439a5693745cd28ec42
https://vbn.aau.dk/da/publications/1e441a6e-e9f1-4321-8721-8bdfd093d58d

Increased synovial galectin-3 induce inflammatory fibroblast activation and osteoclastogenesis in patients with rheumatoid arthritis.

Autor: Nielsen, MA, Køster, D, Greisen, S, Troldborg, A, Stengaard-Pedersen, K, Junker, P, Hørslev-Petersen, K, Hetland, ML, Østergaard, M, Hvid, M, Leffler, H, Kragstrup, TW, Deleuran, B

Publikováno v: Scandinavian Journal of Rheumatology; Jan2023, Vol. 52 Issue 1, p33-41, 9p